Clinical-stage biopharmaceutical company Kodiak Sciences (KOD) saw its shares jump 178% intraday on Sept. 28, after the company reported stellar results for its primary endpoint in the pivotal Phase 3 DAYBREAK trial in wet AMD for its flagship Zenkuda product, as well as its KSI-501 candidate. Zenkuda is an investigational anti-VEGF eye injection to treat serious retinal vascular diseases.
Zenkuda’s endpoint results are notable because they matched or exceeded those of Aflibercept, marketed as Eylea by Regeneron Pharmaceuticals (REGN). The results also show what clinical profile retina specialists are seeking. Because these drugs are injected directly into the eye, researchers aim to minimize application frequency while ensuring maximum effect.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
The results indicated that Zenkuda provided rapid vision and anatomic improvements during loading, followed by maintenance of optimal fluid control; with strict treat-to-dry retreatment criteria, more than half of patients reached a 24-week dosing interval. The AI-guided retreatment algorithm closely mirrors the zero-fluid-tolerance approach, which resulted in improved results.
Kodiak Sciences’ stock jumped on the DAYBREAK results release because it brings the pre-commercial company closer to the market. The company has planned to file a multi-indication biologics license application (BLA) in the fourth quarter of 2026, based on five positive Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion. Investors are likely sensing a commercial breakthrough, which could fuel further stock gains.
About Kodiak Sciences Stock
Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing next-generation therapies for chronic, high-prevalence retinal diseases. Headquartered in Palo Alto, California, the company leverages its proprietary Antibody Biopolymer Conjugate (ABC) platform to engineer longer-acting, more potent treatments targeting conditions like wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
Its lead candidate, tarcocimab tedromer (Zenkuda), is an anti-VEGF antibody biopolymer in late-stage trials, while KSI-501 and KSI-101 target broader disease biology, including inflammation, to potentially reduce injection frequency and improve outcomes. The company has a market capitalization of $5.73 billion.
As the company inches closer to a blockbuster eye drug, Kodiak’s stock has skyrocketed. Over the past 52 weeks, KOD stock has gained 532%. Basically, late-stage clinical data transformed it from a precommercial biotech into a near-term commercial candidate, driving the stock up a whopping 200% over the past five days. It reached an all-time high of $103.93 during this morning's trading but is down 4% from that level.
It has a 14-day relative strength index (RSI) of 91.24, which is firmly in overbought territory, driven by the recent surge. The stock’s price-to-book value ratio (on a forward basis) of 23.51x is significantly higher than the industry average of 3.36x.
www.barchart.com Kodiak Sciences Reported Second-Quarter Loss
The company remains pre-revenue as it gears up for commercialization. Kodiak Sciences’ second-quarter total expenses increased 20.4% year-over-year (YoY) to $66.84 million. However, most of this was made up of research and development expenses of $56.08 million, up 31.2% YoY. Net loss per share climbed by a modest 1.9% from the prior-year period to $1.05.
Kodiak closed Q2 2026 with $125.90 million in cash and equivalents, which it expects will fund ongoing and planned operations into 2027.
Wall Street analysts expect Kodiak Sciences’ loss per share to decline by 14.7% YoY to $0.99 for the third quarter of fiscal 2026. The company’s fiscal 2026 loss per share is expected to decrease by roughly 10% YOY to $3.89. However, next year, loss per share is projected to increase 5.1% annually to $4.09.
What Do Analysts Think About KOD Stock?
After the pivotal Zenkuda study was released, analysts have raised their price target on KOD stock. Analysts at H.C. Wainwright maintained a “Buy” rating and raised the price target from $58 to $96. This followed the DAYBREAK study results. UBS analyst Michael Yee raised the firm’s price target on Kodiak from $80 to $120 and kept a “Buy” rating on the shares, as the analyst believes the results strengthen the comeback thesis with non-inferior efficacy, clean safety, and differentiated durability.
LifeSci Capital raised its price target on Kodiak from $85 to a Street-high $145 and kept an “Outperform” rating. The analyst told investors that aflibercept-like efficacy coupled with differentiated durability is “a best-case scenario outcome.”
Kodiak has become an extremely popular name on Wall Street in a short time, with analysts awarding it a consensus “Strong Buy” rating. Of the seven analysts rating KOD stock, a majority of five analysts have rated it a “Strong Buy,” while two analysts gave it a “Hold” rating. The consensus price target of $87.28 represents an 11% downside from current levels. However, the Street-high price target of $145 indicates a 47% upside.
www.barchart.com On the date of publication, Anushka Dutta did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Kodiak Sciences More Than Doubles on Eye Disease Trial Results Why Super Micro Computer Stock Has More Room to Run ‘Nvidia to Sell Twice as Many Chips as This Next Year’: But Jensen Huang’s Comments Ignore the Market Share Question Why Bank of America Is Betting That Nike Stock Will Fall from Here